Takeda Pharmaceutical (TAK) Asset Writedowns and Impairment (2018 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Asset Writedowns and Impairment of $188.2 million for Q2 2026, up 1055.34% year-over-year from $16.3 million in Q2 2025, and down 42.05% quarter-over-quarter from $324.7 million in Q1 2026.
Takeda Pharmaceutical (TAK) Asset Writedowns and Impairment (2018 - 2026) Analysis & Trends
Takeda Pharmaceutical's Asset Writedowns and Impairment history runs 9 years deep, the most recent figure standing at $188.2 million for Q2 2026.
- In Q2 2026, Asset Writedowns and Impairment rose 1055.34% year-over-year to $188.2 million; the TTM figure through Jun 2026 stood at $1.1 billion (up 108.55% YoY), while the FY2026 annual figure was $968.0 million, up 38.42% from the prior year.
- Asset Writedowns and Impairment for Q2 2026 stood at $188.2 million, down from $324.7 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $823.1 million in Q3 2023, with the low at $14.2 million in Q4 2024.
- The 5-year median for Asset Writedowns and Impairment is $133.7 million (2022), against an average of $206.2 million.
- The sharpest annual moves came in 2022 and 2024: Asset Writedowns and Impairment soared 22639.3% in 2022, then sank 91.8% in 2024.
- Takeda Pharmaceutical's Asset Writedowns and Impairment stood at $42.6 million in 2022, then rose by 20.33% to $51.3 million in 2023, then slumped by 72.26% to $14.2 million in 2024, then surged by 249.41% to $49.7 million in 2025, then surged by 278.75% to $188.2 million in 2026.
- Business Quant data shows TAK's Asset Writedowns and Impairment at $188.2 million in Q2 2026, $324.7 million in Q1 2026, and $49.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 188.20 Mn |
| Jun 30, 2026 | 188.20 Mn |
| Mar 31, 2026 | 324.73 Mn |
| Mar 31, 2026 | 324.73 Mn |
| Dec 31, 2025 | 49.69 Mn |
| Dec 31, 2025 | 49.69 Mn |
| Sep 30, 2025 | 575.42 Mn |
| Sep 30, 2025 | 575.42 Mn |
| Jun 30, 2025 | 16.29 Mn |
| Jun 30, 2025 | 16.29 Mn |
| Mar 31, 2025 | 447.69 Mn |
| Mar 31, 2025 | 447.69 Mn |
| Dec 31, 2024 | 14.22 Mn |
| Dec 31, 2024 | 14.22 Mn |
| Sep 30, 2024 | 67.48 Mn |
| Sep 30, 2024 | 67.48 Mn |
| Jun 30, 2024 | 167.02 Mn |
| Jun 30, 2024 | 167.02 Mn |
| Mar 31, 2024 | 106.18 Mn |
| Mar 31, 2024 | 106.18 Mn |